文献速递前列腺癌

体成分作为雄激素信号抑制治疗指数决定因素的研究

Body composition as a determinant of the therapeutic index with androgen signaling inhibition.
PubMed 文献 · Prostate Cancer Prostatic Dis · 2024-07-17

该研究为NCT02703623的事后分析,纳入186例转移性去势抵抗性前列腺癌(mCRPC)男性,接受8周阿比特龙醋酸酯、泼尼松和阿帕鲁胺(AAPA)治疗,满意反应定义为PSA下降>50%。基线CT测量体成分,发现雄激素合成基因的胚系多态性与ADT后体成分差异相关,且皮下和内脏脂肪增高与AAPA满意反应相关。

要点

  • 雄激素合成基因AKR1C3 rs12529、CYP17A1 rs6162、SRD5A2 rs523349的胚系多态性与ADT后基线体成分差异相关。
  • 皮下脂肪组织指数(SATi,p=0.02)、内脏脂肪组织指数(VATi,p=0.03)和BMI(p=0.04)升高与AAPA满意反应相关。
  • 瘦素与VATi(r=0.47)和SATi(r=0.48)呈正相关。

核心结论

  • 雄激素合成基因的遗传多态性与ADT暴露后体成分差异相关,并需进一步研究作为体成分毒性的候选标志物。
  • 皮下和内脏脂肪增高与ASI治疗反应改善相关。

研究设计与样本

  • NCT02703623的事后分析,纳入186例mCRPC男性,接受8周阿比特龙醋酸酯、泼尼松和阿帕鲁胺(AAPA)治疗,满意反应定义为PSA下降>50%。
  • 基线CT扫描测量体成分,进行胚系DNA全外显子组测序(WES)聚焦类固醇生成基因变异,并检测治疗前血浆脂肪因子水平。

主要发现

  • 雄激素合成3个基因(AKR1C3 rs12529、CYP17A1 rs6162、SRD5A2 rs523349)的胚系多态性与ADT单药(接受AAPA前)基线体成分差异相关。
  • SATi(p=0.02)、VATi(p=0.03)和BMI(p=0.04)升高与AAPA满意反应相关。
  • 瘦素与VATi(r=0.47)和SATi(r=0.48)呈正相关。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Androgen signaling is central to prostate cancer and men's health. Prior data indicates that increasing body fat is unfavorable in the localized setting yet associated with favorable outcomes in men with metastatic disease. Understanding the biological links between adiposity and prostate cancer may optimize the therapeutic index with ASI. We hypothesized that host adiposity and androgen synthesis are linked to the efficacy and toxicity of ASI for men with metastatic castration-resistant prostate cancer (mCRPC). METHODS: A post-hoc analysis was done of NCT02703623 where men with mCRPC (n = 186) were treated for 8 weeks with abiraterone acetate, prednisone, and apalutamide (AAPA), and a satisfactory response was defined as a PSA decline >50%. Body composition was measured on baseline CT scans. Germline DNA WES was performed with a focus on variants in steroidogenic genes. Adipokine levels were measured in pre-treatment plasma. RESULTS: Germline polymorphisms in 3 genes involved in androgen synthesis (AKR1C3 rs12529, CYP17A1 rs6162, SRD5A2 rs523349) were associated with differences in body composition at baseline on ADT alone (prior to receipt of AAPA). Elevated subcutaneous adipose tissue index (SATi, p = 0.02), visceral adipose tissue index (VATi, p = 0.03), and BMI (p = 0.04) were associated with satisfactory response to AAPA. Leptin had positive correlation with VATi (r = 0.47) and SATi (r = 0.48). CONCLUSION: Inherited polymorphisms in androgen synthesis correlated with differences in body composition after exposure to ADT and warrant further investigation as candidate markers for body composition toxicity. Elevated subcutaneous and visceral adiposity were associated with improved response to ASI.

来源:Prostate Cancer Prostatic Dis,查看原文。版权归原作者所有。

引用

  1. Hahn AW, Tidwell RS, Pilie PG, et al. Body composition as a determinant of the therapeutic index with androgen signaling inhibition. Prostate Cancer Prostatic Dis. 2024. PMID: 39019979. doi:10.1038/s41391-024-00870-8

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。